Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.35. This compares to loss of $1.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 21.48%. A quarter ago, it was expected that this company would post a loss of $1.47 per share when it actually produced a loss of $1.46, delivering a surprise of 0.68%. Over the last four quarters, the company ...

Exhibit 99.1 Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress - Rapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy - Aligned with FDA on design for a new Phase 3 trial of NTLA-2001 for the treatment of hereditary ATTR amyloidosis with polyneuropathy, subject to review of IND application; expect to initiate the study by year- end - Plan to present new clinic ...

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2024 financial results and operational highlights in a conference call on May 9, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants sh ...

Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free through the latest follow-up Intellia to host investor webcast on Monday, June 3, at 8 a.m. ET CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an oral presentation f ...

Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free through the latest follow-up Intellia to host investor webcast on Monday, June 3, at 8 a.m. ET CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an oral presentation f ...

公司盈利预期 - Intellia Therapeutics, Inc. (NTLA) 预计在2024年3月报告的季度中，盈利将同比下降，但营收将增加[1] - 分析师们最近对公司的盈利前景变得悲观，这导致了预期盈利的差距[12] - 公司在过去四个季度中有三次超过共识盈利预期[15] 股价表现 - 如果关键数字超过预期，股价可能会上涨；反之，可能会下跌[2]

公司动态 - Intellia Therapeutics, Inc. 宣布在第三期 MAGNITUDE 研究中给首位患者注射了其正在研究的体内基因编辑候选药物 NTLA-2001，用于治疗转甲状腺素（ATTR）淀粉样变性[1] - MAGNITUDE 研究是一项双盲、安慰剂对照的研究，将评估 NTLA-2001 在患有心肌病的 ATTR 淀粉样变性患者中的安全性和有效性[2] - 公司在一项 I 期研究的中期数据显示，单剂 NTLA-2001 治疗导致了负责该疾病的 TTR 蛋白质的深度和持久降低后，开始在第三期 MAGNITUDE 研究中给药[3]

Intellia Therapeutics宣布NTLA-2001治疗在全球关键性第三阶段MAGNITUDE试验中首次给药 - NTLA-2001是一种体内CRISPR基因编辑疗法，旨在通过单剂量治疗来使TTR基因失活，从而预防ATTR淀粉样变性的TTR蛋白产生[1] - MAGNITUDE试验旨在评估NTLA-2001在患有心肌病的ATTR淀粉样变性患者中的疗效和安全性[1] Intellia总裁兼首席执行官John Leonard表示NTLA-2001的第一例患者给药将使公司更接近为患有ATTR淀粉样变性的患者带来潜在的一次性基因编辑治疗 - 该疗法有望为ATTR淀粉样变性患者带来突破性治疗，为未来全球营销申请铺平道路[2] NTLA-2001是基于诺贝尔奖获奖的CRISPR/Cas9技术，有望成为首个一次性治疗ATTR淀粉样变性的疗法 - ATTR淀粉样变性是一种进行性致命疾病，分为遗传性ATTR和野生型ATTR，目前尚无已知治愈方法[3][4]

公司概况 - Intellia Therapeutics是一家处于临床阶段的生物技术公司，尽管公司有一些有前途的项目，但收入很少，持续亏损[3] - Intellia Therapeutics最先进的项目是NTLA-2001，旨在治疗转甲状腺激素淀粉样变性，与Regeneron合作开发[4] - Intellia Therapeutics还有另一种处于临床试验阶段的产品：NTLA-2002，一种用于遗传性血管性水肿的研究性治疗[7] 项目进展 - Intellia Therapeutics已经开始为治疗非遗传性转甲状腺激素淀粉样变性的NTLA-2001进行第3期研究的患者招募，计划在第一季度给第一个患者注射[5] - 如果NTLA-2001在晚期临床试验中取得积极结果，Intellia将在两年内（乐观估计）推出该药物，潜力巨大[6] - Intellia Therapeutics正在进行NTLA-2002的1/2期研究，并计划在今年发布正在进行的试验数据，同时启动第3期研究[7] 财务状况 - Intellia Therapeutics截至2023年底拥有10亿美元的现金、等价物和可交易证券，相比一年前的13亿美元有所减少，管理层认为足以支撑到2026年中期[8] - 即使与Regeneron合作，也不能保证Intellia Therapeutics的项目会取得成功，投资者应考虑风险[9]

The day after Intellia Therapeutics (NTLA -0.84%) updated investors with its results for the fourth quarter on Feb. 23, Cannacord Genuity analyst Whitney Ijem issued a new price target for the stock, estimating that it'd climb by 119% to $73. But, per management's anticipated milestones for 2024, the pre-revenue biotech's most exciting catalysts will be when it reports preliminary data from a pair of its clinical trials later this year. Though it won't have an opportunity to seek regulatory approval for any ...